MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

4.82 -1.83

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.8

Max

4.85

Galvenie mērījumi
By Trading Economics
Ienākumi	-12M -27M
Pārdošana	-5.3M 663K
P/E Sektora vidējais	22.5 63.808
Peļņas marža	-3,998.492
Darbinieki	69
EBITDA	-13M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+183.61% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-195M 949M
Iepriekšējā atvēršanas cena	6.65
Iepriekšējā slēgšanas cena	4.82

Ziņu noskaņojums

By Acuity

29%

71%

71 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. apr. 23:48 UTC

Galvenie ziņu notikumi

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

2026. g. 19. apr. 23:36 UTC

Galvenie ziņu notikumi

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

2026. g. 19. apr. 22:47 UTC

Galvenie ziņu notikumi

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

2026. g. 19. apr. 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026. g. 19. apr. 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026. g. 19. apr. 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

2026. g. 19. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026. g. 19. apr. 23:38 UTC

Galvenie ziņu notikumi

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

2026. g. 19. apr. 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

2026. g. 19. apr. 23:12 UTC

Galvenie ziņu notikumi

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

2026. g. 19. apr. 23:10 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

2026. g. 19. apr. 23:09 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

2026. g. 19. apr. 23:08 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

2026. g. 18. apr. 01:00 UTC

Galvenie ziņu notikumi

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

2026. g. 17. apr. 22:58 UTC

Peļņas

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026. g. 17. apr. 21:32 UTC

Tirgus saruna

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Moody's Downgrades Belgium to A1 -- Market Talk

2026. g. 17. apr. 20:52 UTC

Peļņas

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. apr. 20:29 UTC

Peļņas

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

183.61% augšup

Prognoze 12 mēnešiem

Vidējais 13.67 USD 183.61%

Augstākais 17 USD

Zemākais 11 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

71 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.